Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Natera, Inc. filings document the regulatory record for a Nasdaq-listed diagnostics company focused on cell-free DNA and precision medicine. Recent Form 8-K reports furnish results of operations and financial condition, press releases, investor presentations and exhibit information tied to quarterly and annual reporting.
The company’s proxy materials describe board composition, director elections, committee assignments, executive compensation, equity-award disclosures and stockholder voting matters. Its filings also identify the registered common stock class, Nasdaq Global Select Market listing, governance actions and other material-event disclosures relevant to Natera’s public-company reporting.
Solomon Moshkevich has filed to sell 3,000 shares of common stock of NTRA through Morgan Stanley Smith Barney LLC’s Executive Financial Services from an address at 1 New York Plaza, New York. The filing lists an associated value of $795,751.20 for these shares, with the security traded on NASDAQ and identified by the number 143215382. The shares relate to Performance Shares dated January 14, 2026. The disclosure also reports prior sales over the past three months, including 3,000 shares sold on July 1, 2026 for $818,710.50 and 3,000 shares sold on June 1, 2026 for $655,294.80, along with several smaller transactions in May and July 2026.
Natera, Inc. director and co‑founder Sheena Jonathan reported selling 288 and 191 shares of common stock on July 27 and 28, 2026 at average prices of $260.4908 and $254.0696 per share. The sales were effected to satisfy tax withholding obligations arising from vesting RSUs, under written instructions intended to meet Rule 10b5-1(c) conditions. Separate Caraluna 1 and Caraluna 2 trusts each hold 18,032 shares for beneficiaries, and the reporting person disclaims beneficial ownership of those securities.
Natera, Inc. Executive Chairman Matthew Rabinowitz sold 1,718 shares of Common Stock on July 27, 2026 at an average price of $260.4908 per share. The sale was effected to satisfy tax withholding and remittance obligations in connection with RSU vesting and was made under a written instruction intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. Following the transaction, he directly holds 2,276,125 shares, with an additional 4,000 shares held indirectly by his spouse.
Natera, Inc. reported that its Secretary and Chief Legal Officer, Daniel Rabinowitz, sold a total of 1,887 shares of common stock in two transactions on July 27–28, 2026. The sales, at prices around $260.4908 and a weighted-average $254.0704 per share, were effected to satisfy tax withholding and remittance obligations upon RSU vesting under written instructions intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
Natera, Inc. officer Solomon Moshkevich, President, Clinical Diagnostics, reported selling a total of 2,214 shares of common stock on July 27-28, 2026. The sales were to satisfy tax withholding obligations from vesting RSUs and were executed under written instructions intended to meet Rule 10b5-1(c) conditions.
Natera, Inc. president and chief business officer John Fesko reported open-market sales totaling 1,713 shares of common stock on July 27–28, 2026. These sales were executed to satisfy tax withholding and remittance obligations arising from vesting RSUs and were made under written Rule 10b5-1 trading instructions.
The transactions included 782 shares at $260.4908 per share and 931 shares at a weighted average price of $254.0705, with individual trades on July 28 priced between $254.0696 and $254.3500 per share.
Steven Leonard Chapman, CEO and President of Natera, Inc., reported sales of 5,770 shares of common stock on July 27–28, 2026. He sold 2,190 shares at $260.4908 per share and 3,580 shares at a weighted average price of $254.0704. Footnotes state the shares were sold to satisfy tax withholding and remittance obligations upon vesting of RSUs, under written instructions intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Natera, Inc.’s Chief Financial Officer, Brophy Michael Burkes, reported open-market sales of 5,064 shares of common stock on July 27–29, 2026. Individual trades ranged from 170 to 1,863 shares, with reported prices such as $260.4908 and $249.3800 per share. Certain sales were executed to satisfy tax withholding from vesting RSUs, and all transactions were carried out under a Rule 10b5-1 trading plan adopted June 9, 2025 and modified September 10, 2025.
NTRA filed a notice of proposed sale of 1,863 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services. The shares relate to Restricted Stock Units dated 07/27/2026. The filing also lists several common stock sales during the past three months under and outside a 10b5-1 sales plan for Michael Brophy.
Natera, Inc. associated person Michael Brophy filed a notice of proposed sale of 1,178 shares of common stock, to be handled through Morgan Stanley Smith Barney LLC Executive Financial Services, with the stock listed on NASDAQ. The shares relate to Restricted Stock Units dated 07/26/2026. The filing also lists recent sales of Natera common stock over the past three months, including 3,070 shares on 04/29/2026, 313 shares on 05/01/2026, 482 shares on 05/04/2026, and 782 shares on 07/27/2026, several executed under a Rule 10b5-1 sales plan.